Johns Hopkins

 

Insights from 2023 ASH Annual Meeting
A

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or Venetoclax in Newly Diagnosed Patients With IDH1mut AML - A RWE Study"

By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
0 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi
Videos
15:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment Strategies and QoL Impact in mCR…

Feat. C. Paller
11:47
Johns Hopkins

Current Evidence for Frontline Systematic Treatment in Advanced HCC

Feat. M. Baretti
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosiden…

Feat. A. Ambinder
13:15
Johns Hopkins

Output From the National MDS Study: Utility of Targeted Gene Sequenc…

Feat. A. DeZern
16:27
Johns Hopkins

Targeting BRAF-Altered Glioma in Adults

Feat. K. Schreck
15:49
Johns Hopkins

Severe Aplastic Anemia: What's on the Horizon?

Feat. A. DeZern
09:23
Johns Hopkins

Advancements in Systemic Therapy for Advanced HCC: Where Are We Going

Feat. M. Yarchoan
34:01
MedNews Week

Latest Treatment Strategies and Standard of Care for Pancreatic Canc…

Feat. M. Pishvaian
21:21
Johns Hopkins

KRASG12C Mutation in NSCLC: Current Data and Future Directions

Feat. S. Rosner